Post Lockdown COVID-19 Seroprevalence and Circulation at the Time of Delivery, France
Overview
Authors
Affiliations
Background: To fight the COVID-19 pandemic, lockdown has been decreed in many countries worldwide. The impact of pregnancy as a severity risk factor is still debated, but strict lockdown measures have been recommended for pregnant women.
Objectives: To evaluate the impact of the COVID-19 pandemic and lockdown on the seroprevalence and circulation of SARS-CoV-2 in a maternity ward in an area that has been significantly affected by the virus.
Study Design: Prospective study at the Antoine Béclère Hospital maternity ward (Paris area, France) from May 4 (one week before the end of lockdown) to May 31, 2020 (three weeks after the end of lockdown). All patients admitted to the delivery room during this period were offered a SARS-CoV-2 serology test as well concomitant SARS-CoV-2 RT-PCR on one nasopharyngeal sample.
Results: A total of 249 women were included. Seroprevalence of SARS-CoV-2 was 8%. The RT-PCR positive rate was 0.5%. 47.4% of the SARS-CoV-2-IgG-positive pregnant women never experienced any symptoms. A history of symptoms during the epidemic, such as fever (15.8%), myalgia (36.8%) and anosmia (31.6%), was suggestive of previous infection.
Conclusions: Three weeks after the end of French lockdown, SARS-CoV-2 infections were scarce in our region. A very high proportion of SARS-CoV-2-IgG-negative pregnant women, which is comparable to that of the general population, must be taken into consideration in the event of a resurgence of the pandemic. The traces of a past active circulation of the virus in this fragile population during the spring wave should encourage public health authorities to take specific measures for this independent at-risk group, in order to reduce viral circulation in pregnant patients.
Xu J, Chen J, Wen F, Liu K, Chen Y Heliyon. 2024; 10(3):e24580.
PMID: 38317938 PMC: 10839880. DOI: 10.1016/j.heliyon.2024.e24580.
Vaughan A, Duffell E, Freidl G, Lemos D, Nardone A, Valenciano M BMJ Open. 2023; 13(11):e064240.
PMID: 37931969 PMC: 10632881. DOI: 10.1136/bmjopen-2022-064240.
Accurti V, Gambitta B, Iodice S, Manenti A, Boito S, Dapporto F Int J Environ Res Public Health. 2022; 19(24).
PMID: 36554602 PMC: 9778651. DOI: 10.3390/ijerph192416720.
Lucinde R, Mugo D, Bottomley C, Karani A, Gardiner E, Aziza R PLoS One. 2022; 17(10):e0265478.
PMID: 36240176 PMC: 9565697. DOI: 10.1371/journal.pone.0265478.
SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis.
Azami M, Moradi Y, Moradkhani A, Aghaei A Eur J Med Res. 2022; 27(1):81.
PMID: 35655237 PMC: 9160514. DOI: 10.1186/s40001-022-00710-2.